The treatment of psoriasis vulgaris: 1% topical methotrexate gel

International Journal of Dermatology

Volumn 45, Issue 8, 2006, Pages 965-969

  Eskicirak, Buket ^a,b   Zemheri, Ebru ^a   Cerkezoglu, Arzu ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLCELLULOSE; METHOTREXATE; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; GEL; HISTOPATHOLOGY; HUMAN; MALE; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; SCORING SYSTEM; SKIN BIOPSY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; GELS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; SINGLE-BLIND METHOD;

EID: 33746587436     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02911.x     Document Type: Article

References (25)

1. Patterson JAK, Eisinger M, Haynes BF, et al. Monoclonal antibody 4F2 reactive with basal layer keratinocytes: Studies in the normal and a hyperproliferative state. J Invest Dermatol 1984; 83: 210-213.
2. Fry L. Psoriasi. Br J Dermatol 1988; 119: 445-461.
3. Ross JB. The psoriatic capillary. Its nature and value in the identification of the unaffected psoriatic. Br J Dermatol 1964; 76: 511-518.
4. Bos JD. The pthomechanisms of psoriasis: The skin immune system and cyclosporine. Br J Dermatol 1988; 118: 141-145.
5. Goodfield M, Macdonald Hull S, Holland D, et al. Investigations of the "active"edge of plaque psoriasis: Vascular proliferation precedes changes in epidermal keratin. Br J Dermatol 1994; 131: 808-813.
6. Camp RDR: Psoriasis. In: Champion RH, Burton JL, Burns DA, et al., eds. Textbook of Dermatology, 6th edn. Oxford: Blackwell Science, 1998; 1589-1649.
7. Christophers E, Mrowietz U. Epidermis: Disorders of persistent inflammation, cell kinetics and differentiation. In: Freedberg IM, Eisen AZ, Wolf K, et al., eds. Fitzpatrick's Dermatology in General Medicine, 5th edn. New York: McGraw-Hill, 1999: 495-518.
8. Lebwohl M, Abel E, Zanolli M, et al. Topical therapy for psoriasis. Int J Dermatol 1995; 34: 542-545.
9. Bright RD, Alto P. Methotrexate in the treatment of psoriasis. Cutis 1999; 64: 332-334.
10. Newburger AE, Weinstein GD, McCullough JL. Biological and biochemical actions of methotrexate in psoriasis. J Invest Dermatol 1978; 70: 183-186.
11. Roenigk HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-485.
12. Syed TA, Hadi SM, Qureshi ZA, et al. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: A placebo-controlled, double-blind study. J Cutan Med Surg 2001; 5: 299-302.
13. Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol 1989; 125: 227-230.
14. Sutton L, Swinehart JM, Cato A, et al. A clinical study to determine the efficacy and safety of 1% methotrexate/azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol 2001; 40: 464-467.
15. 903) in a double-blind study. Br J Dermatol 1988; 119: 223-230.
16. Weinstein GD. Methotrexate. Ann Intern Med 1977; 86: 199-204.
17. Weinstein GD, McCullough JL, Eaglstein WH, et al. A clinical screening programme for topical chemotherapeutic drugs in psoriasis. Arch Dermatol 1981; 117: 388-393.
18. Ball MA, McCullogh JL, Weinstein GD. Percutaneous absorption of methotrexate: Effect on epidermal DNA synthesis in hairless mice. J Invest Dermatol 1982; 79: 7-10.
19. Fry L, McMinn RMH. Topical methotrexate in psoriasis. Arch Dermatol 1967; 96: 483-488.
20. Siddiqui O, Roberts MS, Polack AE. Topical absorption of methotrexate: role of dermal transport. Int J Pharmacol 1985; 27: 193-203.
21. Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Méndez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharmacol 2001; 212: 101-107.
22. Van Scott EJ, Reinertson RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J Invest Dermatol 1959; 33: 357.
23. Nurse DS. Effects of antimetabolites on epidermal structures. Arch Dermatol 1963; 87: 258.
24. Comaish S, Julin L. Site of action of methotrexate in psoriasis. Arch Dermatol 1969; 100: 99-105.
25. Al-Suwaidan SN, Feldman SR. Clearance is not realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796-802.